PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

Xiuchao Wang, Xin Li, Xunbin Wei, Haiping Jiang, Chungen Lan, Shengyu Yang, Han Wang, Yanhui Yang, Caijuan Tian, Zanmei Xu, Jiangyan Zhang, Jihui Hao, He Ren

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC'. Together they form a unique fingerprint.

Medicine & Life Sciences